¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Infection, group B strep"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • aerosol infection
    ºÐ¹«°¨¿°
  • airborne infection
    °ø±â¸Å°³°¨¿°
  • anaerobic infection
    ¹«»ê¼Ò±Õ°¨¿°, Çø±â±Õ°¨¿°
  • community infection
    Áö¿ª°¨¿°
  • concurrent infection
    µ¿½Ã°¨¿°
  • contact infection
    Á¢Ã˰¨¿°
  • contagious infection
    Á¢Ã˰¨¿°, Á¢ÃËÀü¿°
  • cross infection
    ±³Â÷°¨¿°
  • cryptogenic infection
    Àẹ°¨¿°
  • defective infection
    °á¼Õ°¨¿°
  • droplet infection
    ºñ¸»°¨¿°
  • dust infection
    ¸ÕÁö°¨¿°
  • disseminated infection
    ÆÄÁ¾°¨¿°
  • double infection
    Áߺ¹°¨¿°
  • exogenous infection
    ¿ÜÀΰ¨¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • nonionic polar group
    ºñÀ̿±ؼº±â
  • open group
    °ø°³Áý´Ü, °³¹æÁý´Ü
  • osmophore group
    ¹ßÇâ´Ü
  • prosthetic group
    ¹èÇÕ±º
  • self-help group
    ÀÚÁ¶Áý´Ü
  • soluble group
    °¡¿ëÇØ±º
  • symmetry group
    ´ëαº
  • taxonomic group
    ºÐ·ùÁý´Ü
  • topological group
    À§»ó±º
  • zymophore group
    È¿¼ÒÀÛ¿ëÁ·
  • prosthetic group-labeled immunoassay
    º¸Á¶±ºÇ¥Áö¸é¿ªºÐ¼®(¹ý)
  • Rh blood group system
    ¾Ë¿¡ÃëÇ÷¾×Çü±º
  • abortive infection
    ºÒ¹ß°¨¿°, ºÒÇö°¨¿°
  • aerial infection
    °ø±â°¨¿°, ÈíÀÔ°¨¿°
  • aerobic infection
    È£±â±Õ°¨¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • group of muscles
    ±ÙÀ°¹«¸®, ±Ù±º(ÐÉÏØ).
  • group practice
    Áý´Ü°³¾÷(̤ËÀ˧ ).
  • group psychotherapy
    Áý´ÜÁ¤½ÅÄ¡·á(ó¢Ó¥ïñãêö½Öû)(¿ä¹ý)
  • group reaction
    Áý´Ü¹ÝÀÀ(̤ËÀËÑËô).
  • group reference value
    Áý´Ü±âÁØ<--ÂüÁ¶>Ä¡
  • group specific C carbohydrate
    ±ºÆ¯ÀÌ C´Ù´çü.
  • group test
    Áý´Ü½ÃÇè(ÊÙËàÌ´).
  • group-specific
    ±ºÆ¯ÀÌÀÇ
  • group-specific C carbohydrate
    ±ºÆ¯ÀÌ C ź¼öÈ­¹°
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • group-specific antigen
    ±º-ƯÀÌÇ׿ø
  • haptenic group
    ÇÕÅÙ±â(¡­Ðñ).
  • hearing aid, group
    Áý´Üº¸Ã»±â
  • high risk group
    °íÀ§Çèµµ±º(Ë­Ëô̴̬˴).
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(¡­Ðñ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • group IV fiber
    Á¦¥³±º¼¶À¯(ÏØàéë«).
  • group IV fiber
    Á¦¥³¤Çí·A.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group antigen
    ±ºÇ׿ø(ÏØù÷ê«).
  • group audiometry
    Áý´Üû·Â°Ë»ç(¹ý)
  • group conformity rating =GCR
    Áý´ÜÇÕÄ¡ µî±ÞºÐ·ù(ÊṴ̬̀ËÄË»ËÓËÈ).
  • group discussion
    Áý´ÜÅäÀÇ(̤ËÀ̬Ëö).
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢(ÊÙËÒ ËôËÑ̬).
  • group dynamics
    Áý´Ü¿ªÇÐ(ÊÙËç ).
  • group file
    ±×·ì È­ÀÏ
  • group hearing aid
    Áý´Üº¸Ã»±â
  • group hospital
    º´¿øÁ¶ÇÕ(ËÓËô̡̰).
  • group incompatibility
    Ç÷¾×±ººÎÀûÇÕ(úìäûÏØ ÝÕîêùê).
  • group medicine
    Áý´Ü<Çùµ¿>Áø·á.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • group translocation
    ¹«¸® ÀüÀ§(ï®êÈ)
  • guanidinium group
    ±¸¾Æ´Ïµð´Ï¿ò±â(Ðñ)
  • guanidino group
    ±¸¾Æ´Ïµð³ë±â(Ðñ)
  • guanido group
    ±¸¾Æ´Ïµµ±â(Ðñ)
  • haptenic group
    ÇÕÅÙ±â(Ðñ)
  • high-mobility group
    °íÀ̵¿µµ ±º(ÍÔì¹ÔÑÓøÏØ)
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(Ðñ)
  • hydroxymethyl group
    ÇÏÀ̵å·Ï½Ã¸ÞÆ¿±â(Ðñ)
  • hypsochromic group
    û»öÀ̵¿±â(ôìßäì¹ÔÑÐñ)
  • imidazole group
    À̴̹ÙÁ¹±â(Ðñ)
  • imino group
    À̹̳ë±â(Ðñ)
  • Inv group
    Inv ±º(ÏØ)
  • ketone group
    ÄÉÅæ±â(Ðñ)
  • labile methyl group
    ºÒ¾ÈÁ¤(ÝÕäÌïÒ)¸ÞÆ¿±â(Ðñ)
  • labile phosphate group
    ºÒ¾ÈÁ¤Àλê±â(ÝÕäÌïÒ×ò߫Ѩ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ANLI antibody-negative with latent infection
APIC Association for Practitioners in Infection Control
AVRI acute viral respiratory infection
BSI behavior status inventory; blood stream infection; borderline syndrome index; bound serum iron; brai...
cEBV chronic Epstein-Barr virus [infection]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ALRI Acute lower respiratory infection
ALRI Acute lower respiratory tract infection
BSI Bloodstream infection
CRBSI Catheter-related bloodstream infection
CRI Catheter-related infection
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • enteral infection
    Àå°ü °¨¿°
  • enterobacter infection
    ¿£Å׷ιÚÅ׸£ °¨¿°
  • enterovirus infection
    Àå ¹ÙÀÌ·¯½º °¨¿°
  • erysipelothrix infection
    ´Üµ¶ °¨¿°
  • focal infection
    ÃÊÁ¡ °¨¿°
  • fusospirochetal infection
    ¹æÃß±Õ ½ºÇÇ·ÎÇìŸ °¨¿°
  • hematogenous infection
    Ç÷Ç༺ °¨¿°
  • human immunodeficiency virus infection
    Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º °¨¿°
  • infection
    °¨¿°, Àü¿°
    1. Àç»ýµÇ°í º¹Á¦µÇ´Â º´Àû ¹Ì»ý¹°ÀÌ Á¶Á÷¿¡ ħ¹üÇÑ °ÍÀ¸·Î¼­ ±¹¼ÒÀûÀÎ ¼¼Æ÷ ¿Ü»ó, µ¶¼ÒÀÇ ºÐºñ, ¶Ç´Â ¼÷ÁÖ¿¡¼­ Ç׿ø-Ç×°À
  • infection allergy
    °¨¿° ¾Ë·¹¸£±â
  • infection immunity
    °¨¿° ¸é¿ª
    ÀÌ¹Ì Ç׿øÀÌ °°°Å³ª °ü·ÃµÈ Ç׿øÀ» °¡Áø ¹Ì»ý¹°¿¡ ÀÇÇÑ ÁúȯÀÌ Á¸ÀçÇϱ⠶§¹®¿¡ Àç°¨¿°¿¡ ´ëÇÏ¿© ÀúÇ×·ÂÀÌ ÀÖ´Â »óÅÂ.
  • infection source
    °¨¿°¿ø, Àü¿°¿ø
  • insect-borne infection
    °ïÃæ ¸Å°³ °¨¿°, °ïÃæ ¸Å°³ Àü¿°
  • laboratory infection
    °Ë»ç½Ç °¨¿°
    °Ë»ç½Ç ³»¿¡¼­ÀÇ ¹Ì»ý¹°¿¡ ÀÇÇÑ °¨¿°.
  • legionella infection
    Lagionella °¨¿°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
droplet infection Infection acquired through the inhalation of droplets or aerosols of saliva or sputum containing virus or other microorganisms expelled by another person during sneezing, coughing, laughing, or talking.
(05 Mar 2000)
inapparent infection Presence of infection in a host without the occurrence of recognizable symptoms or signs.
(05 Mar 2000)
infection 1. <microbiology> Invasion and multiplication of microorganisms in body tissues, which may be clinically unapparent or result in local cellular injury due to competitive metabolism, toxins, intracellular replication or antigen antibody response. The infection may remain localised, subclinical and temporary if the bodys defensive mechanisms are effective. A local infection may persist and spread by extension to become an acute, subacute or chronic clinical infection or disease state. A local infection may also become systemic when the microorganisms gain access to the lymphatic or vascular system.
2. An infectious disease.
(18 Nov 1997)
infection calculus A calculus associated with infection and/or obstruction, usually composed of struvite (magnesium ammonium phosphate).
Synonym: infection calculus.
(05 Mar 2000)
infection control Programs of disease surveillance, generally within health care facilities, designed to investigate, prevent, and control the spread of infections and their causative microorganisms.
(12 Dec 1998)
infection control, dental Efforts to prevent and control the spread of infections within dental health facilities or those involving provision of dental care.
(12 Dec 1998)
infection control nurse A registered nurse with additional education in the monitoring and prevention of nosocomial infections in the client population in an agency.
Synonym: infection control nurse.
(05 Mar 2000)
infection control practitioners Physicians or other qualified individuals responsible for implementing and overseeing the policies and procedures followed by a health care facility to reduce the risk of infection to patients and staff.
(12 Dec 1998)
infection-exhaustion psychosis A psychosis following an acute infection, shock, or chronic intoxication; begins as delirium followed by pronounced mental confusion with hallucinations and unsystematised delusions, and sometimes stupor.
Synonym: febrile psychosis.
(05 Mar 2000)
infection immunity The paradoxical immune status in which resistance to reinfection coincides with the persistence of the original infection.
Synonym: concomitant immunity.
(05 Mar 2000)
infection thread In the formation of root nodules, a cellulosic tube through which Rhizobium cells can travel to reach and infect root cells.
(09 Oct 1997)
infection, urinary tract An infection in the urinary system that begins when microorganisms cling to the opening of the urethra (the canal from the bladder) and begin to multiply. most utis are due to one type of bacteria, e. (escherichia) coli, a normal denisen of the colon. An infection in the urethra leads to inflammation called urethritis. From there bacteria may move up, causing a bladder infection (cystitis) and if the infection is not treated promptly, bacteria may go up the ureters to infect the kidneys (pyelonephritis). Factors leading to uti include any abnormality of the urinary tract (such as a urinary tract malformation or a kidney stone) that obstructs the flow of urine, an enlarged prostate gland that slows the flow of urine, catheters (tubes) in the bladder, diabetes (due to changes of the immune system), and any disorder that suppresses the immune system. Women have more uti than men, probably because a woman's urethra is shorter (allowing bacteria quick access to the bladder) and nearer sources of bacteria from the anus and vagina. For many women, sexual intercourse seems to trigger an infection, as may the use of a diaphragm. Not everyone with a uti has symptoms but symptoms commonly include a frequent urge to urinate and a painful, burning when urinating (dysuria). The urine may look milky or cloudy, even reddish if blood is present. Kidney infection can cause pain in the back or side below the ribs. In children, symptoms may be easily missed or misunderstood. A child with a uti may be irritable, not eat normally, have an unexplained fever, have incontinence or loose bowels, or just not thrive.
(12 Dec 1998)
terminal infection An acute infection, commonly pneumonic or septic, occurring toward the end of any disease and often the cause of death.
Synonym: agonal infection.
(05 Mar 2000)
endogenous infection Infection caused by an infectious agent already present in the body, the previous infection having been inapparent.
(05 Mar 2000)
endosymbiotic infection A situation where a cell that has been infected by a virus is prevented from dividing but is not immediately killed.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • splinter group
    ºÐÆÄ;¼Ò¼öÆÄ
  • tail group
    TAIL UNIT
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á